UB Paderborn / Katalog / Suche / in CDI

ERROR: Record not found

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Metabolic Disposition of Lurbinectedin, a Potent Selective Inhibitor of Active Transcription of Protein-Coding Genes, in Nonclinical Species and Patients

Drug metabolism and disposition, 2022-04, Vol.50 (4), p.327-340

2022

Volltextzugriff (PDF)

Liquid chromatography-tandem mass spectrometric assay for the quantification of galunisertib in human plasma and the application in a pre-clinical study

Journal of pharmaceutical and biomedical analysis, 2019-09, Vol.173, p.169-175

2019

Volltextzugriff (PDF)

Determination of the absolute oral bioavailability of niraparib by simultaneous administration of a 14C-microtracer and therapeutic dose in cancer patients

Cancer chemotherapy and pharmacology, 2018, Vol.81 (1), p.39-46

2018

Volltextzugriff (PDF)

Mechanisms of DNA Methylation Regulatory Function and Crosstalk with Histone Lysine Methylation

Journal of molecular biology, 2024-04, Vol.436 (7), p.168394-168394, Article 168394

2024

Volltextzugriff (PDF)

Liquid chromatography-tandem mass spectrometry assay for the quantification of niraparib and its metabolite M1 in human plasma and urine

Journal of chromatography. B, Analytical technologies in the biomedical and life sciences, 2017-01, Vol.1040, p.14-21

2017

Volltextzugriff (PDF)

Development and validation of a liquid chromatography-tandem mass spectrometry assay for the quantification of lurbinectedin in human plasma and urine

Journal of pharmaceutical and biomedical analysis, 2018-09, Vol.158, p.160-165

2018

Volltextzugriff (PDF)

The histone and non-histone methyllysine reader activities of the UHRF1 tandem Tudor domain are dispensable for the propagation of aberrant DNA methylation patterning in cancer cells

Epigenetics & chromatin, 2020-10, Vol.13 (1), p.44-15, Article 44

2020

Volltextzugriff (PDF)

Mechanism of the pharmacokinetic interaction between methotrexate and benzimidazoles: Potential role for breast cancer resistance protein in clinical drug-drug interactions

Cancer research (Chicago, Ill.), 2004-08, Vol.64 (16), p.5804-5811

2004

Volltextzugriff (PDF)

Liquid chromatography-tandem mass spectrometry assay to quantify plitidepsin in human plasma, whole blood and urine

Journal of pharmaceutical and biomedical analysis, 2017-10, Vol.145, p.137-143

2017

Volltextzugriff (PDF)

Development and validation of LC–MS/MS assays for the quantification of bendamustine and its metabolites in human plasma and urine

Journal of chromatography. B, Analytical technologies in the biomedical and life sciences, 2012-04, Vol.893-894, p.92-100

2012

Volltextzugriff (PDF)

Metabolite profiling of the novel anti-cancer agent, plitidepsin, in urine and faeces in cancer patients after administration of 14C-plitidepsin

Cancer chemotherapy and pharmacology, 2018-09, Vol.82 (3), p.441-455

2018

Volltextzugriff (PDF)

Correction to: Determination of the absolute oral bioavailability of niraparib by simultaneous administration of a 14C-microtracer and therapeutic dose in cancer patients

Cancer chemotherapy and pharmacology, 2018, Vol.81 (1), p.47-47

2018

Volltextzugriff (PDF)

Pharmacokinetics and excretion of 14C–Plitidepsin in patients with advanced cancer

Investigational new drugs, 2017-10, Vol.35 (5), p.589-598

2017

Volltextzugriff (PDF)

Simultaneous quantification of abemaciclib and its active metabolites in human and mouse plasma by UHPLC–MS/MS

Journal of pharmaceutical and biomedical analysis, 2021-09, Vol.203, p.114225-114225, Article 114225

2021

Volltextzugriff (PDF)

Sensitive inductively coupled plasma mass spectrometry assay for the determination of platinum originating from cisplatin, carboplatin, and oxaliplatin in human plasma ultrafiltrate

Journal of mass spectrometry., 2006-09, Vol.41 (9), p.1186-1194

2006

Volltextzugriff (PDF)

Human mass balance study and metabolite profiling of 14C-niraparib, a novel poly(ADP-Ribose) polymerase (PARP)-1 and PARP-2 inhibitor, in patients with advanced cancer

Investigational new drugs, 2017-12, Vol.35 (6), p.751-765

2017

Volltextzugriff (PDF)

Development and validation of an LC-MS/MS method for the quantitative analysis of milciclib in human and mouse plasma, mouse tissue homogenates and tissue culture medium

Journal of pharmaceutical and biomedical analysis, 2020-10, Vol.190, p.113516-113516, Article 113516

2020

Volltextzugriff (PDF)

Phase I and pharmacological trial of lapatinib in combination with gemcitabine in patients with advanced breast cancer

Investigational new drugs, 2015-12, Vol.33 (6), p.1197-1205

2015

Volltextzugriff (PDF)

Corrigendum to “Development and validation of LC–MS/MS assays for the quantification of bendamustine and its metabolites in human plasma and urine” [J. Chromatogr. B: Anal. Technol. Biomed. Life Sci. 893–894 (2012) 92–100]

Journal of chromatography. B, Analytical technologies in the biomedical and life sciences, 2016-05, Vol.1020, p.168-169

2016

Volltextzugriff (PDF)

ABCB1 and ABCG2 limit brain penetration and, together with CYP3A4, total plasma exposure of abemaciclib and its active metabolites

Pharmacological research, 2022-04, Vol.178, p.105954-105954, Article 105954

2022

Volltextzugriff (PDF)

Development and validation of a combined liquid chromatography tandem-mass spectrometry assay for the quantification of aprepitant and dexamethasone in human plasma to support pharmacokinetic studies in pediatric patients

Journal of chromatography. B, Analytical technologies in the biomedical and life sciences, 2021-05, Vol.1171, p.122639, Article 122639

2021

Volltextzugriff (PDF)

Phase I and pharmacokinetic study of SPI-77, a liposomal encapsulated dosage form of cisplatin

Cancer chemotherapy and pharmacology, 2002-03, Vol.49 (3), p.201-210

2002

Volltextzugriff (PDF)

Overestimation of the effect of (fos)aprepitant on intravenous dexamethasone pharmacokinetics requires adaptation of the guidelines for children with chemotherapy-induced nausea and vomiting

Supportive care in cancer, 2022-12, Vol.30 (12), p.9991-9999

2022

Volltextzugriff (PDF)

Relationship between exposure and toxicity in high-dose chemotherapy with cyclophosphamide, thiotepa and carboplatin

Annals of oncology, 2002-03, Vol.13 (3), p.374-384

2002

Volltextzugriff (PDF)

Inductively coupled plasma mass spectrometric analysis of the total amount of platinum in DNA extracts from peripheral blood mononuclear cells and tissue from patients treated with cisplatin

Analytical and bioanalytical chemistry, 2008-05, Vol.391 (2), p.577-585

2008

Volltextzugriff (PDF)

1 – 25 von 248

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(223)
Mit Volltextzugriff
(216)

Publikationsform

Sprache

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(2)

Menü

Weitere Dienste

Einstellungen

Metabolic Disposition of Lurbinectedin, a Potent Selective Inhibitor of Active Transcription of Protein-Coding Genes, in Nonclinical Species and Patients

Liquid chromatography-tandem mass spectrometric assay for the quantification of galunisertib in human plasma and the application in a pre-clinical study

Determination of the absolute oral bioavailability of niraparib by simultaneous administration of a 14C-microtracer and therapeutic dose in cancer patients

Mechanisms of DNA Methylation Regulatory Function and Crosstalk with Histone Lysine Methylation

Liquid chromatography-tandem mass spectrometry assay for the quantification of niraparib and its metabolite M1 in human plasma and urine

Development and validation of a liquid chromatography-tandem mass spectrometry assay for the quantification of lurbinectedin in human plasma and urine

The histone and non-histone methyllysine reader activities of the UHRF1 tandem Tudor domain are dispensable for the propagation of aberrant DNA methylation patterning in cancer cells

Mechanism of the pharmacokinetic interaction between methotrexate and benzimidazoles: Potential role for breast cancer resistance protein in clinical drug-drug interactions

Liquid chromatography-tandem mass spectrometry assay to quantify plitidepsin in human plasma, whole blood and urine

Development and validation of LC–MS/MS assays for the quantification of bendamustine and its metabolites in human plasma and urine

Metabolite profiling of the novel anti-cancer agent, plitidepsin, in urine and faeces in cancer patients after administration of 14C-plitidepsin

Correction to: Determination of the absolute oral bioavailability of niraparib by simultaneous administration of a 14C-microtracer and therapeutic dose in cancer patients

Pharmacokinetics and excretion of 14C–Plitidepsin in patients with advanced cancer

Simultaneous quantification of abemaciclib and its active metabolites in human and mouse plasma by UHPLC–MS/MS

Sensitive inductively coupled plasma mass spectrometry assay for the determination of platinum originating from cisplatin, carboplatin, and oxaliplatin in human plasma ultrafiltrate

Human mass balance study and metabolite profiling of 14C-niraparib, a novel poly(ADP-Ribose) polymerase (PARP)-1 and PARP-2 inhibitor, in patients with advanced cancer

Development and validation of an LC-MS/MS method for the quantitative analysis of milciclib in human and mouse plasma, mouse tissue homogenates and tissue culture medium

Phase I and pharmacological trial of lapatinib in combination with gemcitabine in patients with advanced breast cancer

Corrigendum to “Development and validation of LC–MS/MS assays for the quantification of bendamustine and its metabolites in human plasma and urine” [J. Chromatogr. B: Anal. Technol. Biomed. Life Sci. 893–894 (2012) 92–100]

ABCB1 and ABCG2 limit brain penetration and, together with CYP3A4, total plasma exposure of abemaciclib and its active metabolites

Development and validation of a combined liquid chromatography tandem-mass spectrometry assay for the quantification of aprepitant and dexamethasone in human plasma to support pharmacokinetic studies in pediatric patients

Phase I and pharmacokinetic study of SPI-77, a liposomal encapsulated dosage form of cisplatin

Overestimation of the effect of (fos)aprepitant on intravenous dexamethasone pharmacokinetics requires adaptation of the guidelines for children with chemotherapy-induced nausea and vomiting

Relationship between exposure and toxicity in high-dose chemotherapy with cyclophosphamide, thiotepa and carboplatin

Inductively coupled plasma mass spectrometric analysis of the total amount of platinum in DNA extracts from peripheral blood mononuclear cells and tissue from patients treated with cisplatin

Suchergebnisse filtern